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Abstract
Limbic-predominant age-related TAR-DNA-binding protein-43 (TDP-43) encepha-
lopathy with hippocampal sclerosis pathology (LATE-NC  +  HS) is a neurodegen-
erative disorder characterized by severe hippocampal CA1 neuron loss and 
TDP-43-pathology, leading to cognitive dysfunction and dementia. Polymorphisms 
in GRN, TMEM106B and ABCC9 are proposed as LATE-NC  +  HS risk factors 
in brain bank collections. To replicate these results in independent population-
representative cohorts, hippocampal sections from brains donated to three such 
studies (Cambridge City over 75-Cohort [CC75C], Cognitive Function and Ageing 
Study [CFAS], and Vantaa 85+ Study) were stained with hematoxylin–eosin (n = 744) 
and anti-pTDP-43 (n  =  713), and evaluated for LATE-NC  +  HS and TDP-43 
pathology. Single nucleotide polymorphism genotypes in GRN rs5848, TMEM106B 
rs1990622 and ABCC9 rs704178 were determined. LATE-NC  +  HS (n  =  58) was 
significantly associated with the GRN rs5848 genotype (χ2(2)  =  20.61, P  <  0.001) 
and T-allele (χ2(1) = 21.04, P < 0.001), and TMEM106B rs1990622 genotype (Fisher’s 
exact test, P  <  0.001) and A-allele (χ2(1)  =  25.75, P  <  0.001). No differences in 
ABCC9 rs704178 genotype or allele frequency were found between LATE-NC + HS 
and non-LATE-NC  +  HS neuropathology cases. Dentate gyrus TDP-43 pathology 
associated with GRN and TMEM106B variations, but the association with 
TMEM106B nullified when LATE-NC + HS cases were excluded. Our results indicate 
that GRN and TMEM106B are associated with severe loss of CA1 neurons in the 
aging brain, while ABCC9 was not confirmed as a genetic risk factor for 
LATE-NC  +  HS. The association between TMEM106B and LATE-NC  +  HS may 
be independent of dentate TDP-43 pathology.
INTRODUCTION
Hippocampal sclerosis in old age is a dementing disorder 
characterized by severe loss of pyramidal neurons and gliosis 
in the hippocampal CA1 area. In addition to the anatomi-
cally defined neuron loss, hippocampal sclerosis is frequently 
associated with aggregations of transactive response DNA 
binding protein 43kDa (TDP-43) (15). Recently, neuropatho-
logical changes of limbic-predominant age-related TDP-43 
encephalopathy (LATE) were recognized as disease entity 
(13). Hippocampal sclerosis in old age with TDP-43 pathol-
ogy is thus a subgroup of LATE-NC (LATE-NC  +  HS).
In three European population based studies of older 
people with brain donation, two from the UK and one 
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from Finland, 79-100% LATE-NC  +  HS cases were found 
to have TDP-43 pathology in the hippocampal dentate gyrus 
(6, 10). TDP-43 pathology is also linked to hippocampal 
neuron loss of lesser extent than LATE-NC  +  HS, indicat-
ing that TDP-43 pathology without severe CA1 neuron loss 
may represent a precursor state for LATE-NC  +  HS (6). 
The exact etiological pathophysiology of LATE-NC  +  HS 
is still unclear, but polymorphisms in the progranulin-encoding 
gene GRN (rs5848) (3), transmembrane protein 106B-encoding 
gene TMEM106B (rs1990622) (16), and sulfonylurea receptor 
2-encoding ABCC9 (rs704178, in near-perfect linkage disequi-
librium with rs704180) (14) have emerged as potential risk 
factors within US brain bank-based genome-wide association 
studies (GWAS).
GRN rs5848 TT genotype is associated with lower pro-
granulin levels and has been linked with frontotemporal 
lobar degeneration with TDP-43 positive inclusions (FTLD-
TDP) without GRN mutation (19). Progranulin has direct 
neurotrophic and inflammatory response-modulating func-
tions, and is found to play a role in TDP-43 processing 
(22). TMEM106B is reported to modulate progranulin levels 
(4). ABCC9 has not been associated with FTLD-TDP, 
TDP-43 accumulation or other neurodegenerative diseases 
than LATE-NC + HS, and possible mechanisms of ABCC9 
variation affecting CA1 neuron loss are unclear (17).
No population-representative analyses on GRN rs5848, 
TMEM106B rs1990622 and ABCC9 rs704178 variants in 
LATE-NC + HS have been published. Here, we investigate 
these proposed risk variations in three population-repre-
sentative cohorts of older people, and evaluate their asso-
ciation with LATE-NC  +  HS, which could indicate the 
underlying pathophysiological mechanisms for CA1 neuron 
loss in the aging brain. We also assess if LATE-NC with-
out hippocampal sclerosis is associated with the proposed 
genetic variations.
METHODS
Study design
This study is set within EClipSE (Epidemiological 
Clinicopathological Studies in Europe), which is a col-
laboration of the three European population-represent-
ative longitudinal cohort studies with brain donation 
programs: the Cognitive Function and Ageing Studies 
(CFAS) (multicenter, UK), the Cambridge City over-75s 
Cohort (CC75C, Cambridge, UK), and the Vantaa 85+ 
study (Vantaa, Finland). Cohort profiles, recruiting pro-
cedures and the approach for brain donation have been 
described previously in detail (2, 5, 18). The CC75C had 
2160 participants aged ≥75  years at baseline in 1985, 
CFAS recruited 18226 people aged ≥65 years in 1989–1993, 
and the Vantaa 85+ study comprised 601 people aged 
≥85  years in 1991. In CC75C and CFAS, a stratified 
random subsample of the cohort was approached for 
brain donation, resulting in 11% donation in CC75C 
(n  =  241 at the time of the study) and 3% donation in 
CFAS (n = 562) with known representation of the source 
population. In the Vantaa 85+ study, a consented autopsy 
was performed on 51% (n  =  304) of the cohort. Of these 
1107 EClipSE donations, 131 were excluded due to lack 
of routine neuropathological evaluation (i.e. donations 
were too recent) or missing hematoxylin–eosin-stained 
hippocampal slides with used-up corresponding tissue 
blocks, and further 232 donations were excluded due to 
missing or unreliable deoxyribonucleic acid (DNA) sam-
ples (Figure 1). Thus, 744 EClipSE samples (CC75C 
n  =  216, CFAS n  =  244, Vantaa 85+ n=284) are included 
in the current study (Figure 1). All data collection, 
including brain donation, followed local ethical guidelines 
and approval.
Figure 1. Attrition table indentifying the numbers of samples included in the study by cohort.
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Neuropathological protocol
In CFAS and CC75C, brains were removed as soon as 
possible after death and bisected. One hemisphere was then 
dissected coronally and frozen at  −  80°C. The contralateral 
hemisphere was formalin-fixed for at least six weeks, cut 
in coronal plane, and approximately 1-centimeter (cm)-thick 
samples were paraffin-embedded. In Vantaa 85+, both hemi-
spheres were formalin-fixed, and dissected coronally. The 
right hemisphere was sampled for paraffin-embedding, while 
samples from the left hemisphere were conserved in poly-
ethylene glycol (PEG). PEG-conserved hippocampal tissue 
was reprocessed into paraffin in 2013.
Hippocampal sclerosis
Six- to nine-micrometer (µm)-thick hippocampal sections 
were stained with hematoxylin–eosin. To standardize the 
diagnosis of hippocampal sclerosis across all three EClipSE 
cohorts, available sections were systematically assessed for 
severe neuron loss by an inter-rater-controlled method (6). 
Hippocampal sclerosis was diagnosed as present or absent 
based on severe neuron loss (<5 neurons/ field of view [fov] 
at 200x magnification) in over half  of CA1 fov, gliosis, 
neuronal loss not being explained by an infarct, and no 
obvious neuron loss in other hippocampal areas. Hippocampal 
sclerosis was present in 10/216 CC75C and in CFAS 14/224 
samples (Figure 1). In the Vantaa 85+ study, sections were 
scored hippocampal sclerosis positive when at least one 
hemisphere met the hippocampal sclerosis criteria (n  =  37) 
(Figure 1). It is of note that due to the standardization 
method used in this study, the number of hippocampal 
sclerosis cases in the Vantaa 85+ cohort identified is lower 
than that in the previously published study which used dif-
ferent diagnostic criteria (10).
TDP-43 immunohistochemistry and evaluation
In CC75C and CFAS, 431/460 samples were available for 
TDP-43 assessment, while previous research had exhausted 
the hippocampal area on the remainder. Nine micrometer 
hippocampal sections were immunostained with anti-
pTDP-43 antibody (pSer409/410-2, polyclonal, CosmoBio, 
Japan) (9) at the Cambridge Brain Bank UK.
In Vantaa 85+, 282/284 samples were included in the 
TDP-43 assessment. Hippocampal tissue sections (4μm) 
from the right hemisphere were immunostained with anti-
pTDP-43 antibodies (pSer409/410, clone 11-9, CosmoBio, 
Japan) (10).
Anti-pTDP-43 immunoreactive solid neuronal cytoplas-
mic inclusions (NCI) were evaluated blind to clinical or 
other pathological information as present or absent in the 
hippocampal dentate cell layer. In all three cohorts, TDP-
43 assessment was inter-rater evaluated.
LATE-NC presents with TDP-43 pathology in the amygdala 
at stage 1, and in the hippocampus at stage 2. Figure 2 
illustrates typical hippocampal LATE-NC TDP-43 pathology 
without hippocampal sclerosis (Figure 2A-C) and with hip-
pocampal sclerosis (Figure 2D-F). Dentate NCI pathology 
is highlighted in Figure 2C and F, respectively. In this study, 
Figure 2. A. Section of hippocampus showing dentate, molecular layer 
and CA1 from a case with severe dentate neuronal inclusions but 
minimal cell loss in CA1. B. CA1 from same slide showing a range of 
pathologies immunoreactive for anti-phosphorylated TDP-43 antibody 
including cytoplasmic inclusions and neurites. C. Dentate from same 
slide showing a range of pathologies immunoreactive for 
antiphosphorylated TDP-43 antibody including cytoplasmic inclusions 
and neurites. D. Section of hippocampus showing dentate, molecular 
layer and CA1 from a case with severe dentate neuronal inclusions and 
severe cell loss in CA1 qualifying as HScl. E. CA1 from same slide 
showing a range of pathologies immunoreactive for anti-phosphorylated 
TDP-43 antibody including cytoplasmic inclusions and neurites. F. 
Dentate from same slide showing a range of pathologies immunoreactive 
for anti-phosphorylated TDP-43 antibody including cytoplasmic 
inclusions and neurites. Scale bars: A,D = 200 μm, B,C,E,F = 50 μm.
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dentate cell layer NCI TDP-43 pathology was considered as 
LATE-NC, because TDP-43-stained amygdala sections were 
not available across the EClipSE cohort. Moreover, the den-
tate cell layer has previously been staged as the first hip-
pocampal region affected by TDP-43 pathology after the 
subiculum (7). In cases with hippocampal sclerosis, CA1 and 
subiculum neuron loss may also be so complete that no 
NCI are visible in these regions. Figure S1 shows a LATE-NC 
case with dentate TDP-43 pathology but minimal CA1 pathol-
ogy without hippocampal sclerosis (Figure S1 A-C) and with 
hippocampal sclerosis (Figure S1D-F).
SNP analysis
Single nucleotide polymorphism (SNP) analysis for CC75C/
CFAS was done at the Karolinska Institute, Sweden. A 
TaqMan SNP 7500 genotyping assay on real time PCR 
(Applied Biosystems, CA, USA) was used to determine 
the target SNPs. The target polymorphisms were GRN 
rs5848, TMEM106B rs1990622 and ABCC9 rs704178. Pre-
designed TaqMan SNP Genotype Assays were available 
from ThermoFischer Scientific. For 19 CC75C subjects, 
DNA was extracted from paraffin-embedded blocks, as 
no frozen tissue was available.
In the Vantaa 85+ cohort, genotypes of GRN rs5848 
and TMEM106B rs1990622 were determined from whole-
genome sequencing (WGS) data in 150 subjects (11). Sanger 
sequencing was performed in the remainder samples. Variant 
containing sequences were first amplified using primers listed 
in Table 1. Fragments were run on an ABI3730xl DNA 
Analyzer at the Institute of Molecular Medicine Finland 
and the sequencing data were analyzed using Sequencher 
4.0 analysis software (Applied Biosystems). Genotypes for 
ABCC9 rs704180 were determined from the WGS data in 
150 subjects and the remainder samples were Sanger sequenced 
for this SNP (data not shown). Genotype for ABCC9 rs704178 
was imputed with Beagle 4.1 (version 27Jan18.7e1) using 
the population-specific SISu v3 imputation reference panel 
(https ://doi.org/10.17504/ proto cols.io.nmndc5e). The quality 
of imputed rs704178 genotypes was high and passed post-
imputation quality control (INFO score  =  1, similar MAF 
in our imputed dataset and in the Finnish GnomAD popu-
lation (0.44 vs. 0.41) and 98.6 % concordance between 
imputed and whole-genome sequencing-derived genotypes of 
internal control samples). The number of subjects with reli-
able results for each target SNP is reported in Table 2.
For the EClipSE cohort, G/C SNP rs704178 of gene 
ABCC9 were determined, because the genotype data were 
not available for recommended reference A/G SNP rs704180 
of all three studies. However, these two SNPs are in near 
perfect linkage disequilibrium.
Statistical approach
For CFAS and CC75C samples, TDP-43 inter-rater agree-
ment was assessed calculating Gwet’s Agreement 
Coefficient 2 (AC2) using Agreestat 2015.1 (Advanced 
Analytics, Gaithersburg, MD, USA). Near-perfect agree-
ment was reached for all inter-rater evaluations (CC75C: 
AC2  =  0.99, 95% Confidence Interval [CI]: 0.97–1; CFAS: 
AC2  =  0.98, 95% CI: 0.96–1). For Vantaa 85+ samples, 
TDP-43 pathologies were confirmed by a second and a 
third rater.
Hardy–Weinberg equilibrium (HWE) expected frequen-
cies were calculated and tested using Chi2 goodness of 
fit (χ2(degree of freedom [df ])). Chi2 (χ2(df)) (or Fisher’s 
exact test [FET] when appropriate) was used to test the 
association of genotype or allele frequency and 
LATE-NC  +  HS or TDP-43 pathology. Each SNP was 
analyzed using an additive mode of inheritance (number 
of risk alleles, ie, 0, 1, or 2). ABCC9 rs704178 was 
furthermore analyzed using a recessive mode of inherit-
ance (2 risk alleles  =  1; 0 otherwise), as this has previ-
ously been shown to be appropriate (8, 14, 16). Effect 
size for Cramér’s phi is reported. Logistic regression 
(Odds ratio [OR], 95% CI) was used to test genotype 
associations with LATE-NC  +  HS or TDP-43 pathology 
when taking the effect of age at death and sex into 
consideration. α was set at 0.05. Data were analyzed 
using STATA14 software (Stata Corporation 2015, Texas, 
USA).
RESULTS
Hippocampal sclerosis and TDP-43
All hippocampal sclerosis cases in CC75C and CFAS with 
available TDP-43 staining (n  =  22) were positive for 
hippocampal dentate NCI, while in the Vantaa 85+ 
cohort 26 of the 34 hippocampal sclerosis cases with TDP-
43-immunostained sections presented with dentate NCI. 
However, in the Vantaa 85+ cohort, hippocampal sclerosis 
was evaluated bilaterally, whereas TDP-43 was evaluated 
only on the right hemisphere. All Vantaa 85+ cases with 
hippocampal sclerosis pathology on the right hemisphere 
were positive for dentate TDP-43 NCI on the ipsilateral 
side. The eight Vantaa 85+ hippocampal sclerosis cases which 
were negative for dentate TDP-43 NCI presented with uni-
lateral hippocampal sclerosis on the left hemisphere. 
Therefore, these cases cannot be considered as dentate TDP-
43 NCI negative, and all hippocampal sclerosis cases in the 
EClipSE cohort are referred to as LATE-NC  +  HS in this 
study.
Table 1. PCR primers for Sanger sequencing. PCR = Polymerase chain reaction; SNP = single-nucleotide polymorphism.
SNP Gene Forward primer (5′–3′) Reverse primer (5′–3′)
rs5848 GRN GCCAGGGGTACCAAGTGTTT GCAGGGCGGCAAATCAGA
rs1990622 TMEM106B ACACACGGCATTGTGTTTGATT TGAGATGACCAGCCACTCCA
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LATE-NC + HS, genes and TDP-43
Table 2 presents demographic factors, GRN, TMEM106B 
and ABCC9 genotype frequencies, as well as LATE-NC + HS 
and dentate TDP-43 NCI prevalence for the EClipSE cohort. 
The genotype frequencies did not deviate from HWE.
GRN and LATE-NC + HS
LATE-NC  +  HS associated significantly with the GRN 
rs5848 genotype in EClipSE cohorts (χ2(2)  =  20.61, 
P  <  0.001, phi  =  0.169), presenting more frequently with 
C/T and T/T genotypes compared to the remainder popu-
lation (Table 2). This association remained when adjusting 
for sex and age at death in logistic regression (OR: 2.97, 
95% CI: 1.77–4.98, P  <  0.001). LATE-NC  +  HS cases were 
significantly associated with the risk-allele T in the EClipSE 
cohorts (χ2(1)  =  21.04, P  <  0.001, phi  =  0.121).
TMEM106B and LATE-NC + HS
LATE-NC  +  HS was significantly associated with the 
TMEM106B genotype in EClipSE (FET P  <  0.001, 
phi  =  0.176, Table 2), also when adjusting for sex and age 
at death in logistic regression (OR: 0.31, 95% CI: 0.17–0.54, 
P < 0.001). LATE-NC + HS cases presented more frequently 
with the genotype A/A than the remainder population 
(χ2(1)  =  25.75, P  <  0.001, phi  =  0.123, Table 2).
ABCC9 and LATE-NC + HS
LATE-NC  +  HS did not differ from the remainder popu-
lation in ABCC9 rs704178 genotype or allele frequency, 
irrespective of the analyzed mode of inheritance (additive 
or recessive) (Table 2). Controlling for sex and age at 
death in logistic regression did not influence the result 
(additive MOI: OR: 1.06, 95% CI: 0.59–1.95, P  =  0.824; 
recessive MOI: OR: 0.84, 95% CI: 0.44–1.59, P  =  0.593).
LATE-NC + HS risk genes and TDP-43 pathology
Presence of dentate TDP-43 NCI was significantly associ-
ated with the GRN rs5848 genotypes T/C and T/T 
(χ2(2)  =  18.59, P  <  0.001, phi  =  0.164), also when control-
ling for sex and age at death in logistic regression (OR: 
Table 2. Demographic characteristics of the cohort, and association of GRN rs5848, TMEM106B rs1990622 and ABCC9 rs704178 with LATE-
NC + HS or dentate TDP-43 solid neuronal inclusions. LATE-NC + HS = Limbic-predominant age-related TDP-43 encephalopathy neuropathological 
changes with hippocampal sclerosis; TDP-43 = transactive response DNA binding protein 43 kDa; SD = standard deviation; n = number; 
MOI = mode of inheritance.
No HS-Aging 
(n = 686)
LATE-NC + HS 
(n = 58)
Statistic No dentate TDP-43 
NCI (n = 543)
Dentate TDP-43 
NCI (n = 170)
Statistic
Female (%) 69.1 91.4 χ2(1) = 12.85 70.2 75.9 χ2(1) = 2.08
P < 0.001 P = 0.149
Age at death, mean ± SD 
(years)
89.7 ± 6.2 93.3 ± 4.8 t(742) = −4.33 89.5 ± 6.3 92.2 ± 4.9 t(711) = −5.20
P < 0.001 P < 0.001
GRN rs5848
Genotype, n (%) C/C 342 (51.3) 12 (21.1) χ2(2) = 20.61 280 (53.3) 58 (34.3) χ2(2) = 18.59
C/T 259 (38.8) 33 (57.9) P < 0.001 193 (36.8) 86 (50.9) P < 0.001
T/T 66 (9.9) 12 (21.1) phi = 0.169 52 (9.9) 25 (14.8) phi = 0.164
Allelic frequency, 
(%)
C 70.7 50 χ2(1) = 21.04 71.7 59.8 χ2(1) = 17.01
P < 0.001 P < 0.001
T 29.3 50 phi = 0.121 28.3 40.2 phi = 0.111
TMEM106B rs1990622
Genotype, n (%) A/A 240 (36.6) 38 (66.7) FET 186 (36.1) 81 (48.2) χ2(2) = 10.33
P = 0.006
A/G 313 (47.7) 18 (31.6) P < 0.001 245 (47.5) 72 (42.9)
G/G 103 (15.7) 1 (1.8) phi = 0.176 85 (16.5) 15 (8.9) phi = 0.123
Allelic frequency, 
(%)
A 58.2 82.5 χ2(1) = 25.75 59.8 69.6 χ2(1) = 10.47
P < 0.001 P = 0.001
G 41.8 17.4 phi = 0.123 40.2 30.4 phi = 0.088
ABCC9 rs704178
Genotype, n (%) C/C 137 (20.0) 7 (12.3) χ2(2) = 3.20 114 (21.0) 27 (16.0) χ2(2) = 2.57
C/G 354 (51.7) 36 (63.2) P = 0.202 282 (52.0) 89 (52.7) P = 0.276
G/G 194 (28.3) 14 (24.6) phi = 0.066 146 (26.9) 53 (31.4) phi = 0.060
Recessive MOI C/C, 
C/G
491 (71.7) 43 (75.4) χ2(2) = 0.37 396 (73.1) 116 (68.6) χ2(2) = 1.25
P = 0.544 P = 0.263
G/G 194 (28.3) 14 (24.6) phi = −0.022 146 (26.9) 53 (31.4) phi = 0.042
Allelic frequency, 
(%)
C 45.8 43.9 χ2(1) = 0.16 47 42.3 χ2(1) = 2.33
P = 0.683 P = 0.127
G 54.2 56.1 phi = −0.011 53 57.7 phi = −0.041
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1.68, 95% CI: 1.30–2.17, P  <  0.001), and the T-allele 
(χ2(1)  =  17.01, P  <  0.001, phi  =  0.111). Dentate TDP-43 
NCI was also significantly associated with the TMEM106B 
rs1990622 genotype A/A (χ2(2)  =  10.33, P  =  0.006, 
phi  =  0.123), even when accounted for sex and age at death 
(OR: 0.67, 95% CI: 0.51–0.88, P  =  0.004), and the A-allele 
(χ2(1)  =  10.47, P  =  0.001, phi  =  0.088) (Table 2). The 
distribution of ABCC9 rs704178 genotype and allele did 
not differ between EClipSE subjects with dentate TDP-43 
NCI pathology compared to those without (Table 2). The 
association remained insignificant when controlling for sex 
and age at death in logistic regression (additive MOI: OR: 
1.15, 95% CI: 0.73–1.81, P  =  0.537; recessive MOI: OR: 
1.29, 95% CI: 0.88–1.91, P  =  0.187).
As all LATE-NC  +  HS cases were of TDP-43 positive 
or unknown status ipsilateral to the hippocampal sclerosis 
pathology, analyses on the association of dentate TDP-43 
NCI and LATE-NC  +  HS risk genes were not conducted 
stratified by LATE-NC  +  HS.
The association between dentate TDP-43 NCI and the 
proposed LATE-NC  +  HS risk genes was however evalu-
ated while excluding LATE-NC + HS cases. Dentate TDP-
43 NCI remained significantly associated with GRN rs5848 
genotypes T/C and T/T (χ2(2) = 7.99, P = 0.018, phi = 0.112) 
and the GRN rs5848 T-allele (χ2(1)  =  7.6, P  =  0.006, 
phi  =  0.077) (Table S1), but the association between 
TMEM106B rs1990622 genotype or allele and dentate TDP-
43 NCI became insignificant when LATE-NC  +  HS cases 
were not included in the analyses (Table S1).
DISCUSSION
Previous research, based on US brain bank collections draw-
ing on volunteer and clinical dementia cohorts, has indicated 
that polymorphisms in GRN, TMEM106B and ABCC9 genes 
are associated with hippocampal sclerosis in old age/
LATE-NC  +  HS, but to date no population-representative 
data have been published. Here, we studied three European 
population-representative cohorts and confirmed an associa-
tion of LATE-NC  +  HS with polymorphisms in GRN and 
TMEM106B. The published association of LATE-NC + HS 
with ABCC9 polymorphism could not be reproduced. These 
detected associations of GRN and TMEM106B with 
LATE-NC  +  HS may be related to progranulin expression, 
as literature suggests both GRN and TMEM106B polymor-
phisms to be associated with variation in progranulin 
levels.
Limitations of this study include the overall cohort’s 
sample size, different TDP-43 antibodies and section thick-
ness between the UK and Finnish cohorts, unilateral instead 
of bilateral assessment of hippocampal sclerosis in the UK 
studies and of TDP-43 in all three cohorts, as well as lack 
of proof of causality. It is likely that we did not capture 
all LATE-NC cases in these cohorts as TDP-43 presence 
was only evaluated unilaterally in the hippocampal dentate. 
Further, not all hippocampal sclerosis cases could be veri-
fied as LATE-NC as TDP-43 staining was not available for 
each. Even though the EClipSE collaboration is the largest 
population-representative epidemiological cohort with brain 
donation, numbers of LATE-NC  +  HS cases may still be 
low for a genetic study. The lack of confirmation of the 
ABCC9 locus must therefore be interpreted with caution. 
However, as our population-representative study results give 
very strong independent support to the previously reported 
associations between LATE-NC  +  HS and the polymorphic 
sites in GRN and TMEM106B, it seems likely that func-
tions of these two genes indeed do affect survival of the 
CA1 neurons, at least in older individuals. On the other 
hand, to confirm the hypothesis that variations in GRN 
and TMEM106B contribute to LATE-NC  +  HS neuron 
loss by altered progranulin levels, further studies would need 
to assess the expression of progranulin in association with 
LATE-NC  +  HS.
Important strengths of this study are the high mean age 
and population-representative origin of the cohorts, intro-
ducing minimal selection bias. Studies that previously reported 
polymorphisms in GRN, TMEM106B and ABCC9 as risk 
factors for LATE-NC  +  HS, obtained cases from brain 
banks and Alzheimer’s Disease Centers (1, 8, 14, 16), which 
tend to oversample people with dementia and frequently 
lack sufficient numbers of the oldest old to test hypotheses 
in this age group. Results from these studies may therefore 
not be transferable to the general population. Moreover, 
one of the pitfalls in GWAS studies is multiple testing: 
many candidate polymorphisms are assessed, so associations 
may be significant by chance, even though their clinical 
meaning is not clear. Independent replication of positive 
associations is crucial. Results from GWAS which identified 
proposed LATE-NC  +  HS risk genes (1, 14) have been 
replicated up to now only using similar sources (16). This 
study’s results are the first to verify or challenge previous 
results in an independent cohort, including samples from 
three population-representative cohorts from two 
countries.
Progranulin (encoded by gene GRN at chromosome 17) 
is universally expressed in the central nervous system (CNS) 
during early neuronal development, and is also expressed 
at modest levels in neurons and microglia in adults (21). 
Progranulin is proteolytically broken down into granulin 
peptides by extracellular proteases, mainly elastase, pro-
duced likely by astrocytes and microglia (3). Progranulin 
expression is markedly increased by neuroinflammation in 
association with neurodegenerative disease, where it appears 
to play a modulatory role in tissue damage within the 
CNS to suppress excessive immunity-based microglial acti-
vation and protecting neurons from reactive oxygen species 
and proinflammatory cytokines (21). Most currently known 
GRN mutations causing FTLD-TDP have been reported 
to create null alleles via haploinsufficiency mechanism, 
resulting in reduced protein levels (17). Progranulin may 
act as a potential neurotrophic factor whose loss of func-
tion may cause neurodegeneration in FTLD-TDP or other 
related diseases, and lead to the development of TDP-43-
positive pathology in LATE-NC  +  HS (3). Progranulin 
expression may have effects on cleavage and distribution 
of TDP-43 (8). Notably, the polymorphic rs5848 site in 
the 3’-untranslated region of GRN, which is associated 
with variations in progranulin levels and increased risk 
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of LATE-NC  +  HS, is also part of a binding site for 
microRNA miR-659 (19). miR-659 may confer an increased 
risk for FTLD-TDP and LATE-NC  +  HS through an 
inhibition of progranulin translation, generating an effect 
resembling the biochemical and pathological findings 
observed in GRN-null mutations (19, 21).
Gene TMEM106B (at chromosome 7p21) encodes a trans-
membrane protein, with a preferential expression in the 
frontal lobe (4). Genetic variation in TMEM106B may spe-
cifically modify the development of FTLD in the presence 
of a GRN mutation (12). The TMEM106B rs1990622 vari-
ant, where the C allele regulates GRN expression (4), is 
reported to be protective for LATE-NC  +  HS within a 
cohort of Alzheimer’s disease cases (20). Results from this 
study confirmed GRN rs5848 and TMEM106B rs1990622 
to be associated with LATE-NC + HS. Reduced progranulin 
levels could increase the vulnerability of specific CA1 neuron 
populations, through higher susceptibility for stress and 
inflammatory changes. As all LATE-NC  +  HS cases pre-
sented with ipsilateral dentate TDP-43 NCI, it was not 
possible to analyze the association between LATE-NC + HS 
and the risk genes independent of TDP-43. However, the 
association between TMEM106B and dentate TDP-43 NCI 
was nullified when LATE-NC  +  HS cases were excluded 
from the analyses, which indicates that the association between 
LATE-NC  +  HS and TMEM106B is dependent on 
LATE-NC  +  HS.
Previous studies evaluating the effect of GRN rs5848, 
TMEM106B rs1990622 and progranulin levels/lysosomal 
pathways on neurodegeneration were largely based on 
younger people than those who are at greatest risk of 
LATE-NC  +  HS (9). It is conceivable that progranulin 
alterations might be tolerated at younger age, but that 
with increased age in LATE-NC  +  HS, deterioration of 
cellular defense and clearing mechanisms lower this thresh-
old, leading to CA1 neuron damage.
ABCC9 gene encodes an evolutionarily conserved large 
polypeptide sulfonylurea receptor 2 (SUR2) with multiple 
membrane-spanning domains and multiple levels of biologic 
complexity (17). Intronic SNPs that cluster in the 3′ portion 
of ABCC9 have been associated with a risk for human 
brain illnesses, including sleep disturbances and 
LATE-NC  +  HS (16). SUR2 transcript variants might have 
novel alternative splicing in the mRNAs’ coding region and 
3′ untranslated region (3′UTR) variants (17). The claimed 
LATE-NC  +  HS risk-SNP in ABCC9 is also an expression 
quantitative trait locus, which affects the levels and splice 
variants of brain mRNA transcripts derived from ABCC9 
(17). However, in our study, LATE-NC  +  HS failed to 
associate with ABCC9 rs704178 genotype (evaluated both 
in additive and recessive mode of inheritance) or allele.
The previously reported ABCC9 rs704178 was also not 
associated with TDP-43 pathology in these cohorts. It is 
possible that differences in the cohort selection and case 
definition explain the discrepancy. It is also possible that 
sex could influence the findings, since men at this age are 
a minority of the population and power is therefore limited 
to test for sex differences. Findings by Nelson et al were 
not adjusted for sex (14), but given that the analyses by 
Katsumata et al were adjusted (8), this explanation is likely 
to be insufficient. A mechanistic link between 
LATE-NC  +  HS and ABCC9 variation is unclear, and 
this study did not replicate the previous results. Further 
studies on ABCC9 and LATE-NC  +  HS from different 
source populations are needed to confirm the lack or verify 
the association.
In conclusion, this study confirmed in population-rep-
resentative cohorts that GRN rs5848 C/T and T/T as well 
as TMEM106B rs1990622 A/A genotype are associated 
with loss of CA1 neurons in the aging brain, supporting 
a possible link through lower progranulin levels. ABCC9 
rs704178, however, was not confirmed as a genetic risk 
factor of LATE-NC  +  HS.
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SUPPORTING INFORMATION
Additional supporting information may be found in the 
online version of this article at the publisher’s web site:
Figure S1. A: Section of hippocampus showing dentate, 
molecular layer and CA1 from a case with severe dentate neu-
ronal inclusions but minimal cell loss in CA1; B: CA1 from 
same slide showing very few pathologies immunoreactive 
for anti-phosphorylated TDP-43 antibody; C: Dentate from 
same slide showing a range of pathologies immunoreactive 
for anti-phosphorylated TDP-43 antibody including cyto-
plasmic inclusions and neurites. D: Section of hippocampus 
showing dentate, molecular layer and CA1 from a case with 
severe dentate neuronal inclusions and severe cell loss in 
CA1 qualifying as HScl; E: CA1 from same slide showing few 
pathologies immunoreactive for anti-phosphorylated TDP-
43 antibody; F: Dentate from same slide showing a range of 
pathologies immunoreactive for anti-phosphorylated TDP-
43 antibody including cytoplasmic inclusions and neurites. 
Scale bars: A, D = 200 μm, B, C, E, F = 50 μm.
Table S1. Association of GRN rs5848, TMEM106B rs1990622 
and ABCC9 rs704178 with dentate TDP-43 solid neuronal 
inclusions in subjects without LATE-NC+HS.  
